Supramolecularly assembled antibody drug conjugate for the treatment of non-small cell lung cancer
Antibody drug conjugates (ADCs) are a rapidly expanding class of therapeutics that combine the targeting capabilities of monoclonal antibodies with the cytotoxicity of highly potent chemotherapeutics. Six of the ten current FDA approved ADCs received approval in the past two years alone. However, al...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2021
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/43084 |